References
|
Gong JH, et al. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8: 652-658, 1994. PubMed: 8152260
Klingemann HG, et al. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol. Blood Marrow Transplant. 2: 68-75, 1996. PubMed: 9118301
Tam YK, et al. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum. Gene Ther. 10: 1359-1373, 1999. PubMed: 10365666
Klingemann HG, Miyagawa B. Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 87: 4913-1914, 1996. PubMed: 8639869
Komatsu F, Kajiwara M. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells. Oncol. Res. 10: 483-489, 1998. PubMed: 10338151
Yan Y, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin. Cancer Res. 4: 2859-2868, 1998. PubMed: 9829753
Maki G, et al. Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44. Leukemia 12: 1565-1572, 1998. PubMed: 9766501
Nagashima S, et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91: 3850-3861, 1998. PubMed: 9573023
Tam YK, et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J. Hematother. 8: 281-290, 1999. PubMed: 10417052
|